Navigation Links
Alimera Sciences Reports Fourth Quarter 2012 Financial Results
Date:3/21/2013

at specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Presently, Alimera is focused on diseases affecting the back of the eye, or retina. Its primary product, ILUVIEN, is an intravitreal implant containing fluocinolone acetonide (FAc), a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease.

Forward Looking StatementsThis press release contains "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, Alimera's commercial plans for ILUVIEN in Germany, the UK and France. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual results to differ materially from those projected in its forward-looking statements. Meaningful factors which could cause actual results to differ include, but are not limited to, uncertainty as to Alimera's ability to commercialize, and market acceptance of, ILUVIEN in the EU, as well as other factors discussed in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Alimera's Annual Report on Form 10-K for the year ended December 31, 2011 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2012, which are on file with the Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov. Additional factors may also be set forth in those sections of Alimera's Annual Report on Form 10-K for the year ended December 31, 2012 to be filed with the SEC. In addition to the risks described above and in Alimera's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC, other u
'/>"/>

SOURCE Alimera Sciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Alimera Sciences To Release Fourth Quarter And Fiscal Year 2012 Financial Results
2. Alimera Sciences Participating in Credit Suisse London One-on-One Healthcare Conference
3. Alimera Sciences Names European Management Team
4. Alimera Sciences To Present At Credit Suisse 2012 Healthcare Conference
5. Alimera Sciences To Present At 2012 Stifel Nicolaus Healthcare Conference
6. BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its 2012 Annual Report
7. BioDelivery Sciences to Present at the 25th Annual ROTH Conference
8. Industry Veteran Katrine Bosley Joins Genocea Biosciences Board Of Directors
9. Pressure BioSciences, Inc. to Present at the SeeThruEquity Spring Investor Microcap Forum
10. Neurocrine Biosciences To Present At The 25th Annual Roth Conference
11. PointCross Life Sciences SENDBox and SEND-as-a-Service Prepare Pharma Companies to Comply with the FDAs Upcoming e-Data Submission Mandate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015 Research and Markets ( http://www.researchandmarkets.com/research/vzhr6h/video ) ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 ... communication has been the topic of fascination since the era ... and the Soviet Russia. Earlier even a small ...
(Date:1/23/2015)... Biotherapeutics, Inc. (NASDAQ: NWBO )("NW Bio"), a U.S. ... inoperable solid tumor cancers, announced today that CEO Linda ... Phacilitate Immunotherapy Forum in Washington D.C. ... on January 26 at 10:30 a.m. EST at the Grand ...
(Date:1/23/2015)... Rose, baseball,s all-time hits leader, is the new spokesperson for ... Pharma has announced. "Pete,s a Hall of Famer ... on board with Myoflex," said Ducere Pharma Chief Executive Officer ... is known across all generations. The passion and intensity that ...
Breaking Medicine Technology:Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Pete Rose bets on Myoflex to relieve aches and pains 2
... Local Treatment of Oral Candidiasis in Immunosuppressed Patients in China ... 5 RHEI Pharmaceuticals, Inc. today announced that the final ... dose miconazole in a patented mucoadhesive system, has been initiated ... conducted for submission of the New Drug Application (NDA) to ...
... Orexigen(R) Therapeutics, Inc.,(Nasdaq: OREX ) today ... on its late-stage obesity programs and realign its,management team. ... aspects of these changes are as follows: , ... proof-of-concept Phase 2 trials for OREX-003,(zonisamide and olanzapine to ...
Cached Medicine Technology:RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China 2Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team 2Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team 3
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of Cruz Chiropractic ... treated just about every type of injury that can result from ... same twenty-plus years, the team at Doctors on Liens ... possible doctor. With the combined breadth of experience between ...
(Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved television ... 32nd Annual Miami Breast Cancer Conference planned ... (PER®) , shares that “a fast-growing, virulent” cancer in ... had not followed up her clean mammogram with an ...
(Date:1/22/2015)... Jolla, Calif. (PRWEB) January 22, 2015 ... Assemblymembers Susan Bonilla (D-Concord) and Kristin Olsen (R-Modesto) ... for their leadership in advancing biotechnology, biomedical science, ... Bonilla and Olsen each received the “2014 Life ...
(Date:1/22/2015)... City, Florida (PRWEB) January 22, 2015 IsoComforter, ... cold therapy machine with patented IsoTube design to treat specific ... has introduced the most progressive and easy to use patented ... treat post-operative and sports related orthopedic and muscle injuries. ...
(Date:1/22/2015)... WASHINGTON, DC (PRWEB) January 22, 2015 ... conditions in vulnerable communities and cause financial distress to ... report by analysts at Howard University’s Center on Race ... of dollars in economic activity, payday loans at the ...
Breaking Medicine News(10 mins):Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2
... , WICHITA, Kan., Aug. 10 Operation Rescue ... aimed at stopping abortionist LeRoy Carhart from opening an international late-term ... considered an urgent priority in a larger c a ... in any state. , , In order for Carhart ...
... Chairman ... , ... (PRWEB) August 10, 2009 -- This year,s National Association of Chain Drug Stores ... focused extensively on the healthcare reform debate. During the 52nd annual Conference, experts ...
... , , NEW YORK, Aug. 10 ... leading global information and media company and the CLIO Awards, one of the ... the online entry system, currently open at www.CLIOHealthcare.com for first-ever CLIO ... has been extended. For all work appearing between January 1, 2008 and June ...
... , PITTSBURGH, Aug. 10 ... of diagnostic imaging professional services and Vital Images (Nasdaq: ... analysis software, have partnered to bring Vital Images, advanced visualization ... full suite of software exclusively with its customer base of ...
... idiopathic chronic cholestatic inflammatory liver disease characterized by diffuse ... in bile duct obliteration, biliary cirrhosis, and eventually hepatic ... time of presentation of PSC is mild to severe ... the mechanisms responsible for the abdominal pain in PSC ...
... or ,borrowed, drugs, study found , MONDAY, Aug. 10 (HealthDay ... drugs such as antibiotics and allergy medications with friends, a ... new study. , For example, a teen who,s taking the ... defects -- may give some to a friend who is ...
Cached Medicine News:Health News:Urgent Petition Launched to Block Plans for New International Late-Term Abortion Clinic 2Health News:NACDS Pharmacy and Technology Conference Focuses on Reform 2Health News:NACDS Pharmacy and Technology Conference Focuses on Reform 3Health News:NACDS Pharmacy and Technology Conference Focuses on Reform 4Health News:Nielsen Announces Entry Deadline Extension for the First-Ever CLIO Healthcare Awards 2Health News:Foundation Radiology Group and Vital Images' Partnership Brings Advanced Visualization to Small Medical Communities Nationwide 2Health News:Gallbladder emptying in primary sclerosing cholangitis patients 2Health News:Sharing Prescription Meds Common Among U.S. Teens 2
Agarose IEF is suitable for isoelectric focusing of large molecules and is the gel of choice for many IEF applications and immunochemical detection methods....
Excellent multi purpose agarose Nuclease-free, Gel point (1.5%): 36 1.5 C, EEO: 0.05-0.13 Gel strength (1%): > 1200 g/cm 2 ....
Excellent multi purpose agarose Nuclease-free, Gel point (1.5%): 36 1.5 C, EEO: 0.05-0.13 Gel strength (1%): > 1200 g/cm 2 ....
... purified non-ionic fraction of agar. Forms gel ... concentrations. Can be mounted on microscope slides ... elastic and durable and show little or ... or lipoprotein dyes. Contaminants: ash: ...
Medicine Products: